ATE219674T1 - Zusammensetzung enthaltend capsaicin oder seine analogen und lokalanästhetika - Google Patents

Zusammensetzung enthaltend capsaicin oder seine analogen und lokalanästhetika

Info

Publication number
ATE219674T1
ATE219674T1 AT98911614T AT98911614T ATE219674T1 AT E219674 T1 ATE219674 T1 AT E219674T1 AT 98911614 T AT98911614 T AT 98911614T AT 98911614 T AT98911614 T AT 98911614T AT E219674 T1 ATE219674 T1 AT E219674T1
Authority
AT
Austria
Prior art keywords
capsaicin
site
analogues
anesthesia
pain
Prior art date
Application number
AT98911614T
Other languages
English (en)
Inventor
James N Campbell
Marco Pappagallo
Richard A Meyer
Original Assignee
James N Campbell
Marco Pappagallo
Richard A Meyer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21912426&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE219674(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by James N Campbell, Marco Pappagallo, Richard A Meyer filed Critical James N Campbell
Application granted granted Critical
Publication of ATE219674T1 publication Critical patent/ATE219674T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Anesthesiology (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT98911614T 1997-03-13 1998-03-12 Zusammensetzung enthaltend capsaicin oder seine analogen und lokalanästhetika ATE219674T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4069797P 1997-03-13 1997-03-13
PCT/US1998/004912 WO1998040070A1 (en) 1997-03-13 1998-03-12 Compositions containing capsaicin or capsaicin analogues and a local anesthetic

Publications (1)

Publication Number Publication Date
ATE219674T1 true ATE219674T1 (de) 2002-07-15

Family

ID=21912426

Family Applications (2)

Application Number Title Priority Date Filing Date
AT01204692T ATE481970T1 (de) 1997-03-13 1998-03-12 Zusammensetzungen enthaltend capsaicin oder capsaicin analoge und ein anästhetikum
AT98911614T ATE219674T1 (de) 1997-03-13 1998-03-12 Zusammensetzung enthaltend capsaicin oder seine analogen und lokalanästhetika

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT01204692T ATE481970T1 (de) 1997-03-13 1998-03-12 Zusammensetzungen enthaltend capsaicin oder capsaicin analoge und ein anästhetikum

Country Status (11)

Country Link
US (1) US5962532A (de)
EP (2) EP0998288B2 (de)
JP (1) JP2001515492A (de)
AT (2) ATE481970T1 (de)
AU (1) AU720859B2 (de)
CA (1) CA2285203C (de)
DE (2) DE69841907D1 (de)
DK (2) DK0998288T4 (de)
ES (2) ES2350755T3 (de)
PT (2) PT1201241E (de)
WO (1) WO1998040070A1 (de)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248788B1 (en) 1996-11-06 2001-06-19 The Regents Of The University Of California Therapeutic method with capsaicin and capasicin analogs
US6239180B1 (en) * 1995-11-08 2001-05-29 The Regents Of The University Of California Transdermal therapeutic device and method with capsaicin and capsaicin analogs
CA2304096C (en) 1997-09-18 2003-09-09 Pacira Pharmaceuticals, Inc. Sustained-release liposomal anesthetic compositions
AU752802C (en) 1997-11-14 2006-04-13 Pacira Pharmaceuticals, Inc. Production of multivesicular liposomes
SE9800139D0 (sv) * 1998-01-21 1998-01-21 Astra Ab New use
US6790207B2 (en) 1998-06-04 2004-09-14 Curon Medical, Inc. Systems and methods for applying a selected treatment agent into contact with tissue to treat disorders of the gastrointestinal tract
US6802841B2 (en) 1998-06-04 2004-10-12 Curon Medical, Inc. Systems and methods for applying a selected treatment agent into contact with tissue to treat sphincter dysfunction
IL140899A0 (en) 1998-07-17 2002-02-10 Skyepharma Inc Lipid/polymer containing pharmaceutical compositions and processes for the preparation thereof
EP1301484A2 (de) * 2000-07-20 2003-04-16 Neurogen Corporation Capsaicin-rezeptor-liganden
US20040146590A1 (en) * 2001-03-22 2004-07-29 Iadarola Michael J Molecular neurochirurgie for pain control administering locally capsaicin or resinferatoxin
AU2002322024B2 (en) * 2001-05-31 2008-05-08 Pacira Pharmaceuticals, Inc. Encapsulation of nanosuspensions in liposomes and microspheres
CA2457622A1 (en) * 2001-08-10 2003-02-20 Kava Pharmaceuticals, Inc. Kavalactone compositions and methods of use
EP1450824A4 (de) * 2001-11-02 2005-09-28 Elan Corp Plc Pharmazeutische zusammensetzung
HUP0500200A2 (hu) * 2002-01-17 2005-07-28 Neurogen Corporation Szubsztituált kinazolin-4-ilamin analógok, mint kapszaicin modulátorok és ezeket tartalmazó gyógyszerkészítmények
ES2687970T3 (es) 2002-09-05 2018-10-30 Vanderbilt Royalty Sub L.P. Composiciones y kits para la eliminación de compuestos irritantes de las superficies corporales
EP1551402A4 (de) * 2002-09-23 2009-05-27 Verion Inc Gegen missbrauch gesicherte pharmazeutische zusammensetzungen
US20040161481A1 (en) * 2002-12-18 2004-08-19 Algorx Administration of capsaicinoids
MXPA05006670A (es) * 2002-12-18 2005-10-19 Algorx Pharmaceuticals Inc Administracion de capsaicinoides.
ES2535045T3 (es) 2003-04-10 2015-05-04 Vanderbilt Royalty Sub L.P. Usos y composiciones para administración de capsaicina
JP5148271B2 (ja) * 2004-06-02 2013-02-20 ニューロジズエックス，インコーポレーテッド 疼痛処置のためのカプサイシノイド、局所麻酔薬および／または鎮痒薬を含有する処方物
EP1830836B1 (de) 2004-12-22 2010-11-24 Mestex AG Mischung eines vanilloidrezeptoragonisten mit einer nervenregenerationshemmenden substanz, ihre verwendung für die herstellung eines schmerzmittels und verfahren zur applikation dieses mittels
JP5775246B2 (ja) 2004-12-28 2015-09-09 メステックス アクチェンゲゼルシャフトＭｅｓｔｅｘ Ａｇ 関節痛を治療する薬剤を生成するためのレシニフェラトキシン（ｒｔｘ）の使用方法および前記薬剤を適用する方法
CA2594203C (en) * 2004-12-28 2014-04-29 Mestex Ag Use of a vanilloid receptor agonist together with a glycosaminoglycan or proteoglycan for producing an agent for treating articular pain and method for applying said agent
EP1858495A2 (de) * 2005-02-14 2007-11-28 Neurogesx, Inc. Vorrichtung zur abgabe von trpv1-agonisten
US20060222690A1 (en) * 2005-03-30 2006-10-05 Bley Keith R Low-concentration capsaicin patch and methods for treating neuropathic pain
EA013056B1 (ru) * 2005-04-01 2010-02-26 Ньюроджесэкс, Инк. Масла капсаициноидов и способы их получения и применения
US8916611B2 (en) * 2006-04-28 2014-12-23 Warsaw Orthopedic, Inc. Pharmaceutical removal of neuronal extensions from a degenerating disc
US7943666B2 (en) * 2006-07-24 2011-05-17 Trinity Laboratories, Inc. Esters of capsaicin for treating pain
US7645767B2 (en) * 2006-08-31 2010-01-12 Trinity Laboratories, Inc. Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy
US9943401B2 (en) 2008-04-04 2018-04-17 Eugene de Juan, Jr. Therapeutic device for pain management and vision
US8158682B2 (en) * 2008-09-12 2012-04-17 Vallinex, Inc. Instillation administration of capsaicinoids for the treatment of pain
US8987328B2 (en) * 2008-10-30 2015-03-24 Trinity Laboratories, Inc. Esters of capsaicinoids as dietary supplements
EP2427056A4 (de) * 2009-05-07 2012-08-22 Univ Cincinnati Verfahren zur verhinderung von ischämie während einer peripheren schmerzrezeptionsstimulation
US20110135627A1 (en) * 2009-10-07 2011-06-09 The Inflasoothe Group, Inc. Pain relief composition, system and method
US20130066283A1 (en) 2009-10-23 2013-03-14 Nexisvision, Inc. Corneal Denervation for Treatment of Ocular Pain
EP2490620A4 (de) 2009-10-23 2017-03-22 Forsight Labs, Llc Biegsamer therapeutischer schild für sicht und schmerzen
US8591025B1 (en) 2012-09-11 2013-11-26 Nexisvision, Inc. Eye covering and refractive correction methods for LASIK and other applications
US20120027693A1 (en) 2010-07-27 2012-02-02 Bean Bruce P Methods and compositions for preventing and relieving muscle cramps and for recovery from neuromuscular irritability and fatigue following exercise
CN103281995B (zh) 2010-10-25 2016-04-06 内希斯视觉股份有限公司 识别针对视力的眼睛覆盖物的方法和设备
US20120310140A1 (en) 2010-12-01 2012-12-06 Spinal Modulation, Inc. Directed delivery of agents to neural anatomy
AU2012249773A1 (en) 2011-04-28 2013-11-07 Nexisvision, Inc. Eye covering and refractive correction methods and apparatus having improved tear flow, comfort, and/or applicability
US8678584B2 (en) 2012-04-20 2014-03-25 Nexisvision, Inc. Contact lenses for refractive correction
US12044905B2 (en) 2011-04-28 2024-07-23 Journey1 Inc Contact lenses for refractive correction
US9423632B2 (en) 2012-04-20 2016-08-23 Nexisvision, Inc. Contact lenses for refractive correction
WO2013036961A1 (en) 2011-09-09 2013-03-14 Api Genesis Llc A pain relief composition, comprising a trpv1 selective agonist, and manufacture and uses thereof
US9211274B2 (en) * 2012-02-01 2015-12-15 Warsaw Orthopedic, Inc. TRPV1 compounds in a biodegradable polymer carrier
US9465233B2 (en) 2012-04-20 2016-10-11 Nexisvision, Inc. Bimodular contact lenses
WO2014075084A2 (en) 2012-11-12 2014-05-15 Api Genesis Llc Aqueous based capsaicinoid formulations and methods of manufacture and use
JP6310072B2 (ja) 2013-06-26 2018-04-11 ネクシスビジョン， インコーポレイテッド 屈折矯正のためのコンタクトレンズ
US9956166B2 (en) 2013-09-18 2018-05-01 Sorrento Therapeutics, Inc. Methods for administration and methods for treating cardiovascular diseases with resiniferatoxin
US20150133561A1 (en) 2013-11-12 2015-05-14 Vizuri Health Sciences Llc Aqueous based capsaicinoid formulations and methods of manufacture and use
US9341864B2 (en) 2013-11-15 2016-05-17 Nexisvision, Inc. Contact lenses having a reinforcing scaffold
WO2015116559A1 (en) 2014-01-29 2015-08-06 Nexisvision, Inc. Multifocal bimodulus contact lenses
CA2945818C (en) 2014-04-15 2022-05-03 Vizuri Health Sciences Llc Topical compositions comprising a capsaicinoid for pain relief, manufacture and use
US11634384B2 (en) 2014-11-25 2023-04-25 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists
US9359316B1 (en) 2014-11-25 2016-06-07 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists
EP3463576A4 (de) 2016-05-25 2020-01-15 Concentric Analgesics, Inc. Prodrugs von phenolischen trpv1-agonisten in kombination mit lokalanästhetika und vasokonstriktoren für verbesserte lokalanästhesie
NZ752750A (en) 2016-11-02 2023-05-26 Centrexion Therapeutics Corp Stable aqueous capsaicin injectable formulations and medical uses thereof
WO2018136943A1 (en) 2017-01-23 2018-07-26 Flex Pharma, Inc. Compositions and methods affecting exercise performance
ES3018268T3 (en) 2017-07-20 2025-05-14 Centrexion Therapeutics Corp Compositions and their use for treatment of pain using capsaicin
WO2020008261A2 (en) * 2018-07-05 2020-01-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods and compositions for treating pain and itch
WO2020023794A1 (en) 2018-07-27 2020-01-30 Concentric Analgesics, Inc. Pegylated prodrugs of phenolic trpv1 agonists
EP3840739B1 (de) 2018-08-24 2025-11-12 Centrexion Therapeutics Corporation Verfahren zur sequenziellen dosierung von capsaicin zur behandlung von kniegelenkschmerzen
US11447444B1 (en) 2019-01-18 2022-09-20 Centrexion Therapeutics Corporation Capsaicinoid prodrug compounds and their use in treating medical conditions
US11254659B1 (en) 2019-01-18 2022-02-22 Centrexion Therapeutics Corporation Capsaicinoid prodrug compounds and their use in treating medical conditions
WO2022099284A1 (en) * 2020-11-05 2022-05-12 Young Biopharma, Llc Novel capsaicin analogs and uses thereof
US11357727B1 (en) 2021-01-22 2022-06-14 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US11278494B1 (en) 2021-01-22 2022-03-22 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US12151024B2 (en) 2021-01-22 2024-11-26 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US11033495B1 (en) 2021-01-22 2021-06-15 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
EP4415713A4 (de) 2021-10-14 2025-08-06 Pacira Pharmaceuticals Inc Bupivacain-multivesikuläre liposomformulierungen und verwendungen davon
CN117883414B (zh) * 2024-03-18 2024-06-21 山东第二医科大学 一种长效缓释辣椒素微球及其制备方法和应用
US12251472B1 (en) 2024-05-20 2025-03-18 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US12280149B1 (en) 2024-05-20 2025-04-22 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US12156940B1 (en) 2024-05-20 2024-12-03 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4313958A (en) * 1980-10-24 1982-02-02 The Procter & Gamble Company Method of producing analgesia
US4424205A (en) * 1982-03-18 1984-01-03 The Procter & Gamble Company Hydroxyphenylacetamides having analgesic and anti-irritant activity
US4681897A (en) * 1984-01-16 1987-07-21 The Procter & Gamble Company Pharmaceutical products providing enhanced analgesia
US4939149A (en) * 1988-10-24 1990-07-03 The United States Of America As Represented By The Department Of Health And Human Services Resiniferatoxin and analogues thereof to cause sensory afferent C-fiber and thermoregulatory desensitization
US4997853A (en) * 1988-12-02 1991-03-05 Galenpharma, Inc. Method and compositions utilizing capsaicin as an external analgesic
US5008289A (en) * 1988-12-02 1991-04-16 Galenpharma, Inc. Composition for treating nasal disorders and headaches
US5188837A (en) * 1989-11-13 1993-02-23 Nova Pharmaceutical Corporation Lipsopheres for controlled delivery of substances
US5762963A (en) * 1995-06-07 1998-06-09 Emory University Method and compositions for controlling oral and pharyngeal pain using capsaicinoids

Also Published As

Publication number Publication date
EP1201241B1 (de) 2010-09-22
ES2179473T3 (es) 2003-01-16
JP2001515492A (ja) 2001-09-18
AU720859B2 (en) 2000-06-15
DE69806246T2 (de) 2003-02-06
US5962532A (en) 1999-10-05
ES2179473T5 (es) 2006-03-01
PT1201241E (pt) 2010-12-02
DE69806246D1 (de) 2002-08-01
EP0998288A1 (de) 2000-05-10
EP1201241A3 (de) 2004-01-02
PT998288E (pt) 2002-11-29
WO1998040070A1 (en) 1998-09-17
DK0998288T4 (da) 2005-08-22
DE69841907D1 (de) 2010-11-04
CA2285203A1 (en) 1998-09-17
DE69806246T3 (de) 2006-05-18
DK0998288T3 (da) 2002-10-14
ES2350755T3 (es) 2011-01-26
DK1201241T3 (da) 2010-12-13
HK1027759A1 (en) 2001-01-23
AU6553298A (en) 1998-09-29
EP1201241B8 (de) 2010-10-27
EP0998288B2 (de) 2005-08-03
EP1201241A2 (de) 2002-05-02
EP0998288B1 (de) 2002-06-26
CA2285203C (en) 2005-07-26
ATE481970T1 (de) 2010-10-15

Similar Documents

Publication Publication Date Title
ATE219674T1 (de) Zusammensetzung enthaltend capsaicin oder seine analogen und lokalanästhetika
DK1316308T3 (da) Transdermalt terapeutisk plaster med capsaicin og capsaicin-analoger
DE69634609D1 (de) Analgesiche synergie durch gleichzeitige verabreichung von subanalgesichen doseneines mu-opioidanagonisten und eines kappa - 2- opioidanagonisten
DE69230046D1 (de) 2-Bromomelatonin zur Behandlung von Schlafstörungen
ATE270111T1 (de) Zusammensetzung und methode zur reduktion der toxizität von biologisch-aktiven faktoren
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
LU91544I2 (fr) Alpha alglucosidase
ATE399553T1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
DE59508360D1 (de) Liposomal verkapseltes taxol, seine herstellung und seine verwendung
ATE144420T1 (de) Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen
EP0401903A3 (de) Verwendung von Vanilloiden zur Behandlung von Erkrankungen der Atemwege
ES2106531T3 (es) Compuestos de dibenzoxazepina substituidos en 2, 3, 4, 5, 6, 7, 8, 9 y/o 10, composiciones farmaceuticas y metodos de uso.
ATE137965T1 (de) Verwendung von tomoxetine zur behandlung von funktionsstörungen der niedrigen harnwege
ATE414522T1 (de) Verfahren zur behandlung von akuter und durch übermässige beanspruchung verursachter zerrung und verstauchung mit hyaluronsäure
KR890003390A (ko) 골다공증 및 관련된 장해의 치료방법
DE69111974D1 (de) Verwendung von Lithium zur Behandlung oder Prophylaxe von Molluscum contagiusum.
BRPI0409699A (pt) métodos de indução do efeito diurético, de indução, manutenção ou restauração do efeito diurético de diurético não modificador de adenosina, de manutenção, restauração ou melhoria da função renal em paciente, de indução de diurese, de prevenção do inìcio de deficiência renal em paciente com sobrecarga de fluidos ou chf, de tratamento de paciente que sofre de chf e de melhoria dos resultados globais da saúde, composição farmacêutica e seus usos
ATE200617T1 (de) Pharmazeutische zusammensetzungen zur transdermalen verabreichung von melatonin und/oder seine analoge
ATE297739T1 (de) Endothelin-antagonisten zur behandlung von herzversagen
DE69623316D1 (de) Ctla-8 in kombination mit g-csf oder mit g-csf und il-6, und verwendung vom ctla-8 zur behandlung von infektionen
UA27230C2 (uk) Похідні андростану, заміщені по 16-му положенню четвертинною амонієвою групою, для використання як нервово-м'язових блокаторів та фармацевтична композиція, що здатна викликати нервово-м'язову блокаду
PL327921A1 (en) Compositions containing substances causing blockage of calcium supply, useful in inhibiting growth of cells
DE69131629D1 (de) Behandlung fehlender milchabsonderung beim menschen
DE69218544D1 (de) Verwendung von BMY 14802 zur Behandlung von Angstzuständen bei Patienten mit Benzodiazepin-Entzugserscheinungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
UEP Publication of translation of european patent specification

Ref document number: 0998288

Country of ref document: EP